- Home
- FSBC vs PHAT Comparison
FSBC vs PHAT Comparison
Compare FSBC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSBC | PHAT |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.1M | 894.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FSBC | PHAT |
|---|---|---|
| Price | $36.35 | $10.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $40.75 | $19.50 |
| AVG Volume (30 Days) | 65.3K | ★ 967.8K |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | 28.32 | ★ 42.72 |
| EPS | ★ 2.90 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $29.27 | $91.62 |
| Revenue Next Year | $12.35 | $59.82 |
| P/E Ratio | $12.68 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $22.22 | $2.21 |
| 52 Week High | $42.26 | $18.31 |
Technical Indicators
Market Signals| Indicator | FSBC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 29.75 | 35.03 |
| Support Level | $36.20 | $7.82 |
| Resistance Level | $38.25 | $12.77 |
| Average True Range (ATR) | 1.36 | 0.80 |
| MACD | -0.39 | -0.03 |
| Stochastic Oscillator | 12.25 | 7.28 |
Price Performance
Historical ComparisonAbout FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.